1196 related articles for article (PubMed ID: 34117206)
1. A 59-Year-Old Woman with Extensive Deep Vein Thrombosis and Pulmonary Thromboembolism 7 Days Following a First Dose of the Pfizer-BioNTech BNT162b2 mRNA COVID-19 Vaccine.
Al-Maqbali JS; Al Rasbi S; Kashoub MS; Al Hinaai AM; Farhan H; Al Rawahi B; Al Alawi AM
Am J Case Rep; 2021 Jun; 22():e932946. PubMed ID: 34117206
[TBL] [Abstract][Full Text] [Related]
2. Myocarditis, Pulmonary Hemorrhage, and Extensive Myositis with Rhabdomyolysis 12 Days After First Dose of Pfizer-BioNTech BNT162b2 mRNA COVID-19 Vaccine: A Case Report.
Al-Rasbi S; Al-Maqbali JS; Al-Farsi R; Al Shukaili MA; Al-Riyami MH; Al Falahi Z; Al Farhan H; Al Alawi AM
Am J Case Rep; 2022 Feb; 23():e934399. PubMed ID: 35173141
[TBL] [Abstract][Full Text] [Related]
3. Extensive Cerebral Venous Sinus Thrombosis (CVST) After the First Dose of Pfizer-BioNTech BNT162b2 mRNA COVID-19 Vaccine without Thrombotic Thrombocytopenia Syndrome (TTS) in a Healthy Woman.
Alhashim A; Hadhiah K; Al Khalifah Z; Alhaddad FM; Al ARhain SA; Bin Saif FH; Abid A; Al Gamdi O; Alsulaiman F; AlQarni M
Am J Case Rep; 2022 Feb; 23():e934744. PubMed ID: 35136010
[TBL] [Abstract][Full Text] [Related]
4. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.
Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC
Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336
[TBL] [Abstract][Full Text] [Related]
5. Adverse events following COVID-19 mRNA vaccines: A systematic review of cardiovascular complication, thrombosis, and thrombocytopenia.
Yasmin F; Najeeb H; Naeem U; Moeed A; Atif AR; Asghar MS; Nimri N; Saleem M; Bandyopadhyay D; Krittanawong C; Fadelallah Eljack MM; Tahir MJ; Waqar F
Immun Inflamm Dis; 2023 Mar; 11(3):e807. PubMed ID: 36988252
[TBL] [Abstract][Full Text] [Related]
6. Association of AZD1222 and BNT162b2 COVID-19 Vaccination With Thromboembolic and Thrombocytopenic Events in Frontline Personnel : A Retrospective Cohort Study.
Hviid A; Hansen JV; Thiesson EM; Wohlfahrt J
Ann Intern Med; 2022 Apr; 175(4):541-546. PubMed ID: 35103482
[TBL] [Abstract][Full Text] [Related]
7. [Immune thrombocytopenia after BNT162b2 mRNA COVID-19 vaccination].
Matsumura A; Katsuki K; Akimoto M; Sakuma T; Nakajima Y; Miyazaki T; Fujisawa S; Nakajima H
Rinsho Ketsueki; 2021; 62(11):1639-1642. PubMed ID: 34866090
[TBL] [Abstract][Full Text] [Related]
8. Bullous pemphigoid after second dose of mRNA- (Pfizer-BioNTech) Covid-19 vaccine: A case report.
Alshammari F; Abuzied Y; Korairi A; Alajlan M; Alzomia M; AlSheef M
Ann Med Surg (Lond); 2022 Mar; 75():103420. PubMed ID: 35251600
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of hematological parameters and thrombocytopenia following Pfizer-BioNTech (BNT162b2) SARS-CoV-2 vaccination.
Algaissi A; Alamer E; Jeraiby M; Alomaish A; Elrhima O; Qumayi S; Qasir NA; Areeshi H; Masmali A; Alhazmi A
Saudi Med J; 2022 Jun; 43(6):567-571. PubMed ID: 35675927
[TBL] [Abstract][Full Text] [Related]
10. Thrombotic events following the BNT162b2 mRNA COVID-19 vaccine (Pfizer-BioNTech) in Aotearoa New Zealand: A self-controlled case series study.
Walton M; Tomkies R; Teunissen T; Lumley T; Hanlon T
Thromb Res; 2023 Feb; 222():102-108. PubMed ID: 36634464
[TBL] [Abstract][Full Text] [Related]
11. The BNT162b2 (BioNTech/Pfizer) vaccine had 95% efficacy against COVID-19 ≥7 days after the 2nd dose.
Chagla Z
Ann Intern Med; 2021 Feb; 174(2):JC15. PubMed ID: 33524290
[TBL] [Abstract][Full Text] [Related]
12. [Development of thrombocytopenic purpura following BNT162b2 mRNA COVID-19 vaccination].
Shibata K; Tanaka H; Otani A; Kubo M; Hasegawa A; Amano I
Rinsho Ketsueki; 2021; 62(10):1519-1521. PubMed ID: 34732627
[TBL] [Abstract][Full Text] [Related]
13. Secondary immune thrombocytopenia supposedly attributable to COVID-19 vaccination.
Fueyo-Rodriguez O; Valente-Acosta B; Jimenez-Soto R; Neme-Yunes Y; Inclán-Alarcón SI; Trejo-Gonzalez R; García-Salcido MÁ
BMJ Case Rep; 2021 May; 14(5):. PubMed ID: 34059544
[TBL] [Abstract][Full Text] [Related]
14. Impaired Humoral Response in Renal Transplant Recipients to SARS-CoV-2 Vaccination with BNT162b2 (Pfizer-BioNTech).
Korth J; Jahn M; Dorsch O; Anastasiou OE; Sorge-Hädicke B; Eisenberger U; Gäckler A; Dittmer U; Witzke O; Wilde B; Dolff S; Kribben A
Viruses; 2021 Apr; 13(5):. PubMed ID: 33923063
[TBL] [Abstract][Full Text] [Related]
15. Multiple sites of thrombosis without thrombocytopenia after a second dose of Pfizer-BioNTech COVID-19 vaccine.
Scendoni R; Petrelli C; Giustozzi M; Logullo FO
Int J Immunopathol Pharmacol; 2022; 36():3946320221128534. PubMed ID: 36123789
[TBL] [Abstract][Full Text] [Related]
16. A Case of Immune Thrombocytopenia After BNT162b2 mRNA COVID-19 Vaccination.
King ER; Towner E
Am J Case Rep; 2021 Jul; 22():e931478. PubMed ID: 34285180
[TBL] [Abstract][Full Text] [Related]
17. A COVID-Positive 52-Year-Old Man Presented With Venous Thromboembolism and Disseminated Intravascular Coagulation Following Johnson & Johnson Vaccination: A Case-Study.
Shazley O; Alshazley M
Cureus; 2021 Jul; 13(7):e16383. PubMed ID: 34408937
[TBL] [Abstract][Full Text] [Related]
18. Side Effects of COVID-19 Pfizer-BioNTech mRNA Vaccine in Children Aged 12-18 Years in Saudi Arabia.
Alamer E; Alhazmi A; Qasir NA; Alamer R; Areeshi H; Gohal G; Qadri M; Hashem AM; Algaissi A
Vaccines (Basel); 2021 Nov; 9(11):. PubMed ID: 34835228
[No Abstract] [Full Text] [Related]
19. Safety and Tolerability of the BNT162b2 mRNA COVID-19 Vaccine in Dialyzed Patients. COViNEPH Project.
Polewska K; Tylicki P; Biedunkiewicz B; Rucińska A; Szydłowska A; Kubanek A; Rosenberg I; Rodak S; Ślizień W; Renke M; Dębska-Ślizień A; Tylicki L
Medicina (Kaunas); 2021 Jul; 57(7):. PubMed ID: 34357013
[No Abstract] [Full Text] [Related]
20. Aseptic meningitis after SARS-CoV-2 Pfizer/BioNTech vaccination.
Dupon V; Arnaert S; Van Haute E; Vulsteke F; Diet G; De Schoenmakere G
Acta Clin Belg; 2022 Dec; 77(6):976-979. PubMed ID: 34882515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
